B Cell Profiling in Patients with Pemphigus Vulgaris

Pemphigus vulgaris is a severe, socially significant autoimmune disease associated with autoanti- bodies to the desmoglein 3 antigen. The disease affects all age groups, beginning at 18 years of age; the mor- tality rate of pemphigus can reach as high as 50%, depending on a patient's age and a number of other fac- tors. There is no highly selective or personalized therapy for pemphigus vulgaris at the moment. One of the well-known therapeutic approaches to the disease is to use rituximab, an anti-CD20 antibody that can help achieve B cell depletion in peripheral blood. To solve the problem of nonspecific elimination of B cells in pa- tients with pemphigus vulgaris, it is reasonable to use specific immunoligands, their choice being based on an assessment of the level of autoantibodies specific to each of the fragments of desmoglein. In this work, the proportion of autoreactive B cells in patients diagnosed with pemphigus vulgaris is found to be 0.09-0.16%; a positive correlation was revealed between the antibody level and the number of autoreactive B cells to var- ious fragments of desmoglein.